On March 9, Novo Nordisk said it will sell its blockbuster Wegovy and Ozempic drugs through Hims & Hers Health.<\/p>\n
Barclays says alternative data suggests customer momentum has improved since the March 9 collaboration announcement.<\/p>\n
The firm sees stronger visibility into the company\u2019s growth trajectory later this year.<\/p>\n
Shares of Hims & Hers Health (HIMS) gained nearly 6% in afternoon trading on Wednesday after Barclays turned more bullish on the telehealth company, citing accelerating growth prospects and signs of improving momentum following its partnership with Novo Nordisk (NVO).<\/p>\n
The HIMS stock later pared the gains and ended the session 1.33% higher.<\/p>\n
See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox<\/a><\/p>\n Barclays Sees Post-Novo Inflection <\/p>\n Barclays raised its price target on Hims & Hers to $39 from $29, implying a 21% upside from the stock\u2019s last closing price. The firm also maintained an \u2018Overweight\u2019 rating on the HIMS stock.<\/p>\n Barclays said a combination of strong demand for weight-loss offerings and contributions from other businesses is expected to drive a significant acceleration in revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA) during the second half of 2026.<\/p>\n With HIMS shares largely flat year to date, Barclays said investors could begin to re-rate the stock as visibility into the back-half growth ramp improves.<\/p>\n The brokerage also pointed to a \u201cclear inflection\u201d following Hims & Hers\u2019 partnership with Novo Nordisk, announced on March 9. According to Barclays, its proprietary and alternative data indicate improving trends since the partnership was announced, reinforcing confidence in the company\u2019s growth outlook.<\/p>\n On Wednesday, Hims & Hers shares traded above the $30 level<\/a>, a key resistance area that capped gains in April and sparked selling pressure in the weeks that followed. Sustaining a move above that threshold could help reinforce the bullish sentiment surrounding the stock.<\/p>\n Morningstar Sees Momentum Rebound <\/p>\n A recent Morningstar note also pointed to improving momentum at Hims & Hers. The firm said it expects growth to pick up starting in the second quarter, citing the timing of the company\u2019s partnership with Novo Nordisk.<\/p>\n That view aligns with Barclays\u2019 assessment, which said the collaboration is already showing signs of driving an inflection in growth trends.<\/p>\n HIMS Stock: What Retail Traders Feel <\/p>\n On Stocktwits, retail sentiment for HIMS improved to \u2018extremely bullish\u2019 from \u2018bullish\u2019 a day ago, while message volume was \u2018high,\u2019 unchanged in the last 24 hours.<\/p>\n Message activity for HIMS rose more than 120% over the past seven days, while the watcher count increased by 0.3% during the same period.<\/p>\n According to data from Koyfin, four of the 16 analysts covering HIMS rate it \u2018Buy\u2019 or higher, while 11 rate it \u2018Hold\u2019 and only one rates it \u2018Strong Sell.\u2019 The 12-month average target on the stock is $26.61, representing a potential upside of about 18% from the last close.<\/p>\n HIMS stock has lost nearly 7% year-to-date.<\/p>\n Also See: KMX Stock Slides Nearly 9% \u2014 CarMax CEO Flags Operational Challenges, Says Costs Are Too High<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n Aveek Bhowmik has no position in any of the stocks mentioned in this article. StockTwits’ news team content is for informational purposes only and is not intended as investment advice. For more, see our editorial policy<\/a>. This article was originally published on StockTwits<\/a>.<\/p>\n Related:<\/p>\n","protected":false},"excerpt":{"rendered":"On March 9, Novo Nordisk said it will sell its blockbuster Wegovy and Ozempic drugs through Hims &…\n","protected":false},"author":2,"featured_media":112996,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[29791,621,20756,272],"class_list":["post-112995","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-barclays","tag-hims","tag-hims-hers-health","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116785930981760505","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/112995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=112995"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/112995\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/112996"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=112995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=112995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=112995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}